Everything we've seen

1. ?Sep 14, 1:45 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   IQV is up 1.77% today with 120 minutes remaining — a meaningful but not dramatic move. No headlines are available to attribute the move to a specific catalyst, which is common and not disqualifying. The macro context (T10Y2Y at 1.9σ below trend) slightly favors defensives in a bear-flattening environment, and IQV as a healthcare/CRO name has some defensive characteristics, which is mildly supportive. However, the move is modest (~1.77%), sitting below the 2-5% threshold where momentum evidence becomes more compelling. With 120 minutes left there is ample time for continuation but also for mean reversion if the move was driven by thin early flow rather than sustained institutional buying. No reversal pattern is evident from the data provided. On balance, the setup is a borderline continuation — no strong reason to expect a fade, but no clear accelerant either. Assigning a slight lean toward continuation consistent with the system's bias toward action when evidence is neutral-to-positive.

2. !Sep 14, 1:45 PMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   IQV is up 1.77% today with 120 minutes remaining — a meaningful but not dramatic move. No headlines are available to attribute the move to a specific catalyst, which is common and not disqualifying. The macro context (T10Y2Y at 1.9σ below trend) slightly favors defensives in a bear-flattening environment, and IQV as a healthcare/CRO name has some defensive characteristics, which is mildly supportive. However, the move is modest (~1.77%), sitting below the 2-5% threshold where momentum evidence becomes more compelling. With 120 minutes left there is ample time for continuation but also for mean reversion if the move was driven by thin early flow rather than sustained institutional buying. No reversal pattern is evident from the data provided. On balance, the setup is a borderline continuation — no strong reason to expect a fade, but no clear accelerant either. Assigning a slight lean toward continuation consistent with the system's bias toward action when evidence is neutral-to-positive.

3. ❖Sep 10, 11:30 AMnewsvia finnhub

   Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

   NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

4. ❖Sep 10, 9:56 AMnewsvia finnhub

   IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?

   IQVIA Holdings has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

5. ❖Sep 9, 5:13 PMnewsvia finnhub

   IQVIA Announces Pricing of Senior Notes

   RESEARCH TRIANGLE PARK, N.C., September 09, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the "Notes"). The proceeds from the Notes offering will be used to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees an

6. ❖Sep 9, 8:15 AMnewsvia finnhub

   IQVIA Announces Offering of Senior Notes

   RESEARCH TRIANGLE PARK, N.C., September 09, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the "Notes").

7. ❖Sep 8, 10:31 AMnewsvia finnhub

   IQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?

   The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

8. ?Sep 4, 11:05 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   IQV is down 1.86% intraday, a moderate but not extreme move. The macro context shows elevated 5Y5Y inflation forwards (2.33, +1.7σ above trend), which pressures rate-sensitive and growth-oriented sectors — IQV as a CRO/healthcare IT name with a meaningful growth multiple is modestly exposed to this headwind, providing some support for continued selling pressure. The sole headline references a software rebound extending Moat Index gains, which if anything is a mild sector tailwind that could cap further downside. With 280 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend, but the news backdrop is not aligned with the downside direction. The move at -1.86% shows real flow but isn't large enough on its own to strongly signal capitulation or conviction selling. Balancing: moderate macro headwind supports continuation, but the sector headline is mildly counter-directional and the move hasn't crossed into 'strong conviction' territory (>2.5-3%). Assigning minimum threshold probability — the evidence is roughly in balance with a slight lean toward continuation given macro context.

9. !Sep 4, 11:05 AMsignalseverity -0.02

   Agent 7 — Day Trader — day_trade_skipped

   IQV is down 1.86% intraday, a moderate but not extreme move. The macro context shows elevated 5Y5Y inflation forwards (2.33, +1.7σ above trend), which pressures rate-sensitive and growth-oriented sectors — IQV as a CRO/healthcare IT name with a meaningful growth multiple is modestly exposed to this headwind, providing some support for continued selling pressure. The sole headline references a software rebound extending Moat Index gains, which if anything is a mild sector tailwind that could cap further downside. With 280 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend, but the news backdrop is not aligned with the downside direction. The move at -1.86% shows real flow but isn't large enough on its own to strongly signal capitulation or conviction selling. Balancing: moderate macro headwind supports continuation, but the sector headline is mildly counter-directional and the move hasn't crossed into 'strong conviction' territory (>2.5-3%). Assigning minimum threshold probability — the evidence is roughly in balance with a slight lean toward continuation given macro context.

10. ❖Sep 4, 11:02 AMnewsvia finnhub

    1 Profitable Stock with Solid Fundamentals and 2 That Underwhelm

    Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

11. ❖Sep 4, 12:40 AMnewsvia finnhub

    Software Rebound Extends Moat Index Gains

    The S&P 500 gained 2.72% and reached a record high in August, with energy leading the market as crude prices rose. Read more here.

12. ✓Sep 3, 8:09 PMdecisionacted

    Agent 20 — SIR Price/Volume — buy

    [cluster_break_up] From 2026-08-07 through 2026-08-18, IQV carved out a dense price cluster in the $236–$244 range on low-to-moderate volume (750K–1.5M), with down-day volume consistently lighter than up-day volume — a textbook SIR accumulation base. The path then began a sustained upward drift, with the Aug 19–Aug 21 surge ($249→$260) on volumes of 1.2M–1.8M signaling the initial cluster break. Today's session (2026-09-03, close $271.62, volume 2.0M, z-score +2.95 vs. 20-day ADV of 1.2M) represents a decisive upper cluster break: price cleared the Aug 24–Sep 02 consolidation band ($258–$263) on volume roughly 1.67× the trailing mean, with the 2-D scatter path moving firmly up-and-right. The multi-session confirmation across Aug 19–Sep 03 — not just the single latest dot — gives the pattern credibility under SIR methodology. Risks: A reversal back below the $261–$263 consolidation band on elevated volume (≥1.5M) would indicate distribution absorbing today's breakout and would invalidate the cluster_break_up read. Additionally, the elevated 5-year inflation breakeven (T5YIFR at 2.33, +1.7σ above trend) poses a macro headwind for rate-sensitive sectors, and any repricing of rate expectations could compress Health Care/CRO multiples and undermine the demand signal embedded in today's volume surge.

13. ❖Sep 3, 5:15 PMnewsvia finnhub

    IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster

    RESEARCH TRIANGLE PARK, N.C., September 03, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.

14. ❖Sep 3, 2:10 PMnewsvia finnhub

    VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast

    Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.

15. ❖Sep 3, 11:30 AMnewsvia finnhub

    Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

    TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

16. ❖Sep 2, 3:42 PMnewsvia finnhub

    This Payroll Software Company Bought Back 20% of Its Shares and the Stock Has Nearly Doubled Since April

    While most software companies were retreating, Paycom made an aggressive and unconventional bet on itself, and the market delivered a verdict that caught even seasoned analysts off guard.

17. ❖Sep 2, 1:24 PMnewsvia finnhub

    Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?

    The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.

18. ❖Aug 31, 5:52 PMnewsvia finnhub

    Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment

    As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.

19. ?Aug 31, 11:20 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down 1.60% today, which is a moderate but not outsized move. There are no catalysts visible — no headlines, no sector-specific macro tailwinds or headwinds directly applicable to IQV (a healthcare data/CRO firm). The macro context around elevated mortgage rates is sector-agnostic for IQV and provides no directional signal. With 265 minutes remaining (roughly 4+ hours), there is ample time for the move to either continue or reverse. The move size of ~1.6% is meaningful but below the 2-5% threshold that would signal strong conviction flow. Without news to anchor the move, it could reflect sector rotation, broad market pressure, or unwinding of a position rather than a fundamental repricing. Given the bounded risk profile of the system (tight -1.5% stop, +3% target, forced EOD close), and the principle that borderline reads resolve in favor of taking the trade, I assign a continuation probability of exactly 0.5 — momentum is present but there is no strong amplifying factor to push conviction higher.

20. !Aug 31, 11:20 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    IQV is down 1.60% today, which is a moderate but not outsized move. There are no catalysts visible — no headlines, no sector-specific macro tailwinds or headwinds directly applicable to IQV (a healthcare data/CRO firm). The macro context around elevated mortgage rates is sector-agnostic for IQV and provides no directional signal. With 265 minutes remaining (roughly 4+ hours), there is ample time for the move to either continue or reverse. The move size of ~1.6% is meaningful but below the 2-5% threshold that would signal strong conviction flow. Without news to anchor the move, it could reflect sector rotation, broad market pressure, or unwinding of a position rather than a fundamental repricing. Given the bounded risk profile of the system (tight -1.5% stop, +3% target, forced EOD close), and the principle that borderline reads resolve in favor of taking the trade, I assign a continuation probability of exactly 0.5 — momentum is present but there is no strong amplifying factor to push conviction higher.

21. ❖Aug 31, 6:50 AMnewsvia finnhub

    Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

    Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.

22. ?Aug 28, 8:32 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — buy

    [not executed — reserve_floor_or_cash] [cluster_break_up] The PV path tells a clear two-phase story. From 2026-08-03 through 2026-08-18, IQV coiled in a tight price cluster spanning roughly $228–$244, traversed on declining or routine volume (lows of 750K on 2026-08-13 and 855K on 2026-08-12), forming a classic low-energy consolidation node in 2-D space. The break began on 2026-08-19 ($249.28, 1.2M) and accelerated powerfully on 2026-08-20 ($256.05, 1.8M — 1.5× the 20-day ADV), vaulting the path decisively up and to the right away from the prior cluster; that single session's volume alone matched today's elevated print and confirmed fresh demand absorbing the float. The subsequent drift from $256–$262 on diminishing but still-solid volume (1.3M→1.2M→1.1M→901K→1.3M→1.2M) is characteristic post-breakout consolidation, not distribution, and today's 1.8M down-day (-0.24%) is a single-bar event on flat price action that does not reverse the broader up-and-right path through 2-D space. Risks: A decisive close back below the breakout shelf near $249–$252 on volume exceeding 1.5M would signal the cluster break was a false move and invalidate the bullish read. Additionally, because IQV operates in Health Care rather than rate-sensitive sectors, the elevated mortgage rate print (6.66, +1.8σ) is not a direct headwind, but a broader risk-off rotation triggered by macro deterioration could compress the entire sector and drag the path back into the prior cluster.

23. ?Aug 6, 12:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down 2.75% today with no attributable headline, suggesting this is either broad sector rotation or quiet institutional distribution rather than a news-driven spike that might quickly reverse. The macro context (5Y breakeven 1.9σ below trend) signals a deflationary/risk-off tilt that does not particularly help healthcare services/CRO names like IQV — low inflation expectations can pressure revenue growth assumptions in contract research. With 190 minutes remaining there is ample time for the move to extend, though the absence of a clear catalyst also means there's no obvious secondary catalyst to accelerate selling into the close. No reversal signals are apparent from the data provided. The setup is modest — no strong reason to expect a fade, but also no high-conviction continuation pressure — so this sits in the ordinary momentum band. Slight lean toward continuation given the magnitude of move and risk-off macro tone.

24. !Aug 6, 12:35 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    IQV is down 2.75% today with no attributable headline, suggesting this is either broad sector rotation or quiet institutional distribution rather than a news-driven spike that might quickly reverse. The macro context (5Y breakeven 1.9σ below trend) signals a deflationary/risk-off tilt that does not particularly help healthcare services/CRO names like IQV — low inflation expectations can pressure revenue growth assumptions in contract research. With 190 minutes remaining there is ample time for the move to extend, though the absence of a clear catalyst also means there's no obvious secondary catalyst to accelerate selling into the close. No reversal signals are apparent from the data provided. The setup is modest — no strong reason to expect a fade, but also no high-conviction continuation pressure — so this sits in the ordinary momentum band. Slight lean toward continuation given the magnitude of move and risk-off macro tone.

25. ?Aug 5, 11:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up 3.19% today with no attributable headline, suggesting this is flow-driven — likely institutional buying or short covering. The move is meaningful in magnitude and represents real conviction. With 280 minutes remaining there is ample time for continuation. However, the macro backdrop is modestly cautionary: 5-year breakeven inflation (T5YIE) is printing 1.9σ below trend, signaling a deflationary/risk-off undertone that does not directly favor CRO/healthcare IT names but is also not a direct headwind. No sector-specific tailwind is identifiable from the macro brief. The absence of news means we cannot confirm a catalyst that would sustain buying pressure, but absence of news is not disqualifying. The 3.19% move sits at the lower end of the 'meaningful' range and may attract profit-taking rather than follow-through buying, particularly without a clear catalyst. Overall, momentum bias is modestly positive but conviction is limited — probability set just above threshold to reflect directional lean without overstating the setup.

26. !Aug 5, 11:05 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    IQV is up 3.19% today with no attributable headline, suggesting this is flow-driven — likely institutional buying or short covering. The move is meaningful in magnitude and represents real conviction. With 280 minutes remaining there is ample time for continuation. However, the macro backdrop is modestly cautionary: 5-year breakeven inflation (T5YIE) is printing 1.9σ below trend, signaling a deflationary/risk-off undertone that does not directly favor CRO/healthcare IT names but is also not a direct headwind. No sector-specific tailwind is identifiable from the macro brief. The absence of news means we cannot confirm a catalyst that would sustain buying pressure, but absence of news is not disqualifying. The 3.19% move sits at the lower end of the 'meaningful' range and may attract profit-taking rather than follow-through buying, particularly without a clear catalyst. Overall, momentum bias is modestly positive but conviction is limited — probability set just above threshold to reflect directional lean without overstating the setup.

27. ?Aug 5, 9:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up ~2.96% today with no attributable headline catalyst visible, suggesting this is likely flow-driven or sector rotation. The macro context (T5YIE at 1.9σ below trend, signaling lower real rate expectations) is mildly supportive for growth/healthcare services names like IQV, as lower inflation expectations can ease discount rate pressure on future earnings. However, there is no strong sector-specific tailwind explicitly tied to IQV, and the absence of news means we cannot confirm whether the move is driven by sustained institutional buying or a one-time block. With 350 minutes remaining there is ample time for continuation, which prevents a time-decay discount. The move magnitude (just under 3%) is meaningful but not extreme, reducing the chance of an overextension fade. No reversal signals or volume anomalies are noted. Overall, this reads as a modest momentum continuation setup with no compelling reason to fade it — assigning a slight edge to continuation.

28. !Aug 5, 9:55 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    IQV is up ~2.96% today with no attributable headline catalyst visible, suggesting this is likely flow-driven or sector rotation. The macro context (T5YIE at 1.9σ below trend, signaling lower real rate expectations) is mildly supportive for growth/healthcare services names like IQV, as lower inflation expectations can ease discount rate pressure on future earnings. However, there is no strong sector-specific tailwind explicitly tied to IQV, and the absence of news means we cannot confirm whether the move is driven by sustained institutional buying or a one-time block. With 350 minutes remaining there is ample time for continuation, which prevents a time-decay discount. The move magnitude (just under 3%) is meaningful but not extreme, reducing the chance of an overextension fade. No reversal signals or volume anomalies are noted. Overall, this reads as a modest momentum continuation setup with no compelling reason to fade it — assigning a slight edge to continuation.

29. ?Jul 30, 10:15 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down 3.71% today, a meaningful move indicating real selling pressure with institutional conviction behind it. No headlines are available to explain the catalyst, but as noted in the guidance, absence of news does not disqualify the move — large intraday selloffs in healthcare IT/CRO names like IQV often reflect sector rotation, earnings pre-positioning, or block-level selling that plays out over the full session. The macro context (T5YIE at 1.5σ below trend) suggests subdued inflation expectations, which is mildly unfavorable for defensively positioned healthcare names as it implies a risk-on tilt that could redirect flows away from IQV. With 330 minutes remaining — essentially a full trading session still ahead — there is ample time for continuation. No reversal pattern is evident from the data provided; the move is not described as fading from highs. Counterbalancing factors: without volume data or news, there is uncertainty about whether the selling is exhausted or ongoing; a 3.71% drop also increases mean-reversion risk. On balance, momentum and time remaining tip the read toward modest continuation, but confidence is limited without volume or catalyst confirmation.

30. !Jul 30, 10:15 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    IQV is down 3.71% today, a meaningful move indicating real selling pressure with institutional conviction behind it. No headlines are available to explain the catalyst, but as noted in the guidance, absence of news does not disqualify the move — large intraday selloffs in healthcare IT/CRO names like IQV often reflect sector rotation, earnings pre-positioning, or block-level selling that plays out over the full session. The macro context (T5YIE at 1.5σ below trend) suggests subdued inflation expectations, which is mildly unfavorable for defensively positioned healthcare names as it implies a risk-on tilt that could redirect flows away from IQV. With 330 minutes remaining — essentially a full trading session still ahead — there is ample time for continuation. No reversal pattern is evident from the data provided; the move is not described as fading from highs. Counterbalancing factors: without volume data or news, there is uncertainty about whether the selling is exhausted or ongoing; a 3.71% drop also increases mean-reversion risk. On balance, momentum and time remaining tip the read toward modest continuation, but confidence is limited without volume or catalyst confirmation.

31. ?Jul 28, 6:04 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [exhaustion] The 20-day PV path tells a clear story in two phases: a gradual drift lower from ~$210 on 2026-07-16 down to $198.52 on 2026-07-22 on unremarkable volume (837K–1.3M), forming a tight cluster in the $198–$213 band on ADV of ~1.2M. Then on 2026-07-28, IQV explodes to $243.31 on 8.0M shares — a volume z-score of 16.53 versus the trailing 20-day mean — representing a single-session volume spike roughly 6.7× the recent average. Under SIR's 2-D framework, this is the hallmark of an exhaustion/climax bar: price hits a new extreme and volume is unprecedented, with no prior multi-session accumulation path leading into it. The absence of any persistent up-and-right accumulation drift in the preceding 20 days (the path was actually trending down-and-flat through late July) means the single dot at ($243.31, 8.0M) sits as an isolated extreme, not the culmination of an orderly breakout. Risks: The primary risk to this bearish/cautious read is that today's spike is a genuine earnings-driven re-rating; if the next 2–3 sessions hold above $230 on sustained (not collapsing) volume, the bar could retroactively serve as the anchor of a new accumulation cluster rather than a climax top. Additionally, the macro tailwind of a 10-year inflation breakeven 1.7σ below trend favors long-duration/growth health care names, which could provide a fundamental floor that limits mean-reversion.

32. ?Jul 27, 6:04 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — buy

    [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-07-06 through 2026-07-24, IQV traced a tight consolidation cluster spanning roughly $198–$210 on consistently subdued volume (ranging from 747K on 2026-07-10 to a peak of 1.4M on 2026-07-23), with the 20-day mean ADV of just 1.2M confirming the range was formed on low-conviction, routine turnover. Today's bar on 2026-07-27 closes at $213.26 — decisively above the upper edge of that cluster — on 3.1M shares, a volume z-score of +5.53 standard deviations above the trailing 20-day mean; this is precisely the SIR cluster_break_up signature: a prior low-volume price band followed by a breakout bar on materially expanding demand. Importantly, the setup is not a naked single-bar spike: the path into today's break shows a constructive two-day recovery off the 2026-07-22 low of $198.52 (on only 1.0M shares each on 7/22 and 7/23), suggesting the float was already being absorbed before today's confirming surge. Risks: A failure to hold above the $207–$208 cluster ceiling on any near-term pullback — particularly if accompanied by volume expansion on down-days — would re-classify this as a false breakout and flip the read to distribution; additionally, because today's bar is a high-z-score single-session event, absence of follow-through volume over the next 2–3 sessions would reduce conviction materially toward exhaustion territory.

33. ?Jul 17, 2:02 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down 2.10% intraday with no attributable headline catalyst, suggesting this is either broad sector rotation or institutional repositioning. The macro context shows the 10-year inflation breakeven (T10YIE) at 2.22, running 1.6 sigma below its 24-month trend — a deflationary lean that could pressure healthcare/CRO names like IQV if investors perceive pricing/revenue headwinds. However, IQV is not a pure long-duration play, so the macro tailwind for continuation is moderate at best. With 104 minutes remaining there is sufficient time for the move to extend, but the move is already at the lower boundary of the 2-5% meaningful conviction range and without a clear news catalyst or sector-wide selling narrative confirmed, there is no strong evidence of a second leg down. No reversal signals are evident, but no acceleration signal either. Assigning baseline continuation probability at 0.50 — the evidence marginally supports continuation given the size of the move and time remaining, but the lack of catalyst and the deflationary macro context (which is ambiguously negative for this name) prevent a higher conviction read.

34. !Jul 17, 2:02 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    IQV is down 2.10% intraday with no attributable headline catalyst, suggesting this is either broad sector rotation or institutional repositioning. The macro context shows the 10-year inflation breakeven (T10YIE) at 2.22, running 1.6 sigma below its 24-month trend — a deflationary lean that could pressure healthcare/CRO names like IQV if investors perceive pricing/revenue headwinds. However, IQV is not a pure long-duration play, so the macro tailwind for continuation is moderate at best. With 104 minutes remaining there is sufficient time for the move to extend, but the move is already at the lower boundary of the 2-5% meaningful conviction range and without a clear news catalyst or sector-wide selling narrative confirmed, there is no strong evidence of a second leg down. No reversal signals are evident, but no acceleration signal either. Assigning baseline continuation probability at 0.50 — the evidence marginally supports continuation given the size of the move and time remaining, but the lack of catalyst and the deflationary macro context (which is ambiguously negative for this name) prevent a higher conviction read.

35. ?Jul 16, 10:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up 1.87% today, a meaningful but not outsized move. There are no news catalysts visible, which is neutral rather than bearish — large institutional flows frequently drive moves without same-day headlines. The macro context (T5YIE at 1.6σ below trend, suppressed inflation expectations) is modestly supportive for growth-oriented healthcare/data services names like IQV, as lower real rate anxiety reduces discount rate pressure. However, several factors temper conviction: (1) the move is below the 2% threshold where momentum tends to be self-reinforcing; (2) with 340 minutes remaining the session is still early-to-mid, meaning there is ample time for a fade but also ample time for continuation — this is roughly neutral on the time dimension; (3) no sector catalyst or volume signal is available to confirm institutional accumulation. With no strong reversal signal and a bounded risk structure (tight stop at -1.5%, target at +3%), the default lean is mild continuation. Assigning 0.53 — slightly above the action threshold but not a high-conviction setup.

36. !Jul 16, 10:05 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    IQV is up 1.87% today, a meaningful but not outsized move. There are no news catalysts visible, which is neutral rather than bearish — large institutional flows frequently drive moves without same-day headlines. The macro context (T5YIE at 1.6σ below trend, suppressed inflation expectations) is modestly supportive for growth-oriented healthcare/data services names like IQV, as lower real rate anxiety reduces discount rate pressure. However, several factors temper conviction: (1) the move is below the 2% threshold where momentum tends to be self-reinforcing; (2) with 340 minutes remaining the session is still early-to-mid, meaning there is ample time for a fade but also ample time for continuation — this is roughly neutral on the time dimension; (3) no sector catalyst or volume signal is available to confirm institutional accumulation. With no strong reversal signal and a bounded risk structure (tight stop at -1.5%, target at +3%), the default lean is mild continuation. Assigning 0.53 — slightly above the action threshold but not a high-conviction setup.

37. ?Jul 13, 12:50 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up 1.85% today, a moderate but meaningful intraday move suggesting real directional flow. No news headlines are present, which is neutral — absence of news does not disqualify momentum. The macro context shows a T10Y2Y reading 2.1σ below its 24-month trend, which is modestly supportive for defensive/healthcare-adjacent names like IQV (a CRO/life sciences data company) relative to rate-sensitive sectors. With 175 minutes remaining there is meaningful time for continuation, though not a full session runway. The move is below the 2% threshold that would signal strong conviction, so this is a moderate momentum read with no clear reversal signals or fade pattern noted. No reason to expect a strong fade; the setup qualifies as ordinary momentum. Probability set modestly above threshold.

38. !Jul 13, 12:50 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    IQV is up 1.85% today, a moderate but meaningful intraday move suggesting real directional flow. No news headlines are present, which is neutral — absence of news does not disqualify momentum. The macro context shows a T10Y2Y reading 2.1σ below its 24-month trend, which is modestly supportive for defensive/healthcare-adjacent names like IQV (a CRO/life sciences data company) relative to rate-sensitive sectors. With 175 minutes remaining there is meaningful time for continuation, though not a full session runway. The move is below the 2% threshold that would signal strong conviction, so this is a moderate momentum read with no clear reversal signals or fade pattern noted. No reason to expect a strong fade; the setup qualifies as ordinary momentum. Probability set modestly above threshold.

39. ?Jul 8, 1:16 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down 2.68% intraday with no headline catalyst visible, suggesting institutional selling or sector rotation rather than a news-driven spike. The move has meaningful magnitude — real flow is behind it. However, several factors temper continuation confidence: (1) 150 minutes remaining is ample time but also means the move has already progressed significantly and some mean-reversion risk accumulates; (2) the macro context shows a compressed yield curve (T10Y2Y 2σ below trend), which is modestly supportive of defensive/healthcare-adjacent names like IQV over purely cyclical sectors — this doesn't strongly favor further selling; (3) no news catalyst means we can't confirm whether the driver is ongoing or exhausted. Without a clear sector tailwind for the downside and given the absence of any escalating negative narrative, this reads as ordinary momentum carry rather than a high-conviction continuation. Probability set at 0.52 — slight lean toward continuation given the magnitude of the move and the principle that 2%+ moves reflect real conviction, but no strong amplifying factors justify a higher reading.

40. !Jul 8, 1:16 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    IQV is down 2.68% intraday with no headline catalyst visible, suggesting institutional selling or sector rotation rather than a news-driven spike. The move has meaningful magnitude — real flow is behind it. However, several factors temper continuation confidence: (1) 150 minutes remaining is ample time but also means the move has already progressed significantly and some mean-reversion risk accumulates; (2) the macro context shows a compressed yield curve (T10Y2Y 2σ below trend), which is modestly supportive of defensive/healthcare-adjacent names like IQV over purely cyclical sectors — this doesn't strongly favor further selling; (3) no news catalyst means we can't confirm whether the driver is ongoing or exhausted. Without a clear sector tailwind for the downside and given the absence of any escalating negative narrative, this reads as ordinary momentum carry rather than a high-conviction continuation. Probability set at 0.52 — slight lean toward continuation given the magnitude of the move and the principle that 2%+ moves reflect real conviction, but no strong amplifying factors justify a higher reading.

41. ?Jul 8, 11:06 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down ~3% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The move is meaningful in magnitude, implying real conviction from whoever initiated it. However, several factors temper the continuation probability: (1) with 280 minutes remaining there is ample time but also ample time for mean reversion; (2) the macro context shows a flat-to-inverted yield curve (T10Y2Y at 0.36, 2σ below trend), which is modestly supportive of defensives and unhelpful for growth-oriented healthcare IT names like IQV — this is mildly supportive of the down move continuing rather than reversing; (3) no news is present to clarify the catalyst, which cuts both ways but per framework does not push probability below 0.5; (4) a ~3% move without news can sometimes represent a one-time large seller working through an order, after which price stabilizes or rebounds. Balancing sustained move magnitude and macro headwinds against the absence of a clear catalyst and the risk of a mid-session recovery, this is a modest continuation setup warranting a slight lean toward continuation.

42. !Jul 8, 11:06 AMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    IQV is down ~3% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The move is meaningful in magnitude, implying real conviction from whoever initiated it. However, several factors temper the continuation probability: (1) with 280 minutes remaining there is ample time but also ample time for mean reversion; (2) the macro context shows a flat-to-inverted yield curve (T10Y2Y at 0.36, 2σ below trend), which is modestly supportive of defensives and unhelpful for growth-oriented healthcare IT names like IQV — this is mildly supportive of the down move continuing rather than reversing; (3) no news is present to clarify the catalyst, which cuts both ways but per framework does not push probability below 0.5; (4) a ~3% move without news can sometimes represent a one-time large seller working through an order, after which price stabilizes or rebounds. Balancing sustained move magnitude and macro headwinds against the absence of a clear catalyst and the risk of a mid-session recovery, this is a modest continuation setup warranting a slight lean toward continuation.

43. ❖Jul 6, 10:28 AMnewsvia finnhub

    Medpace: The Recovery Narrative Looks Premature

    Medpace's outlook turns cautious as bookings, backlog, and cancellations worsen vs. CRO peers. Click for more on MEDP stock.

44. ❖Jul 6, 10:00 AMnewsvia finnhub

    Medpace Stock Outlook Turns on Backlog Quality and Cancellations

    MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.

45. ✓Jul 6, 9:50 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    IQV is up 6.48% intraday — a move of this magnitude signals meaningful institutional conviction and real order flow. No news is present to explain the catalyst, but the guidance explicitly notes that absence of news is not a disqualifier; large moves often precede or coincide with unreported flow (earnings pre-announcement, M&A rumors, analyst upgrades, index rebalancing, etc.). With 355 minutes remaining (nearly a full session still ahead), there is ample time for continuation. The macro context — 10Y inflation breakevens running 1.6σ below trend — is mildly supportive for growth/long-duration sensitive equities like IQV (a CRO/health data company with meaningful long-duration earnings characteristics), as lower real rate expectations tend to support multiple expansion. There is no reversal signal evident: the move is characterized as a clean directional gap/run rather than a fade off highs. Key risks: (1) no confirmed catalyst means the move could be unwinding once the initial flow exhausts; (2) a 6.5% move is large enough that profit-taking into the close is plausible. On balance, the evidence favors modest continuation — the move has size, time is ample, macro is not adverse, and no reversal pattern is flagged. Probability set at 0.58, reflecting solid but not high-conviction continuation.

46. ❖Jul 6, 5:55 AMnewsvia finnhub

    My Top 5 Pharma Stocks Wall Street Ignores

    Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they lag AI names. Click for the picks.

47. ▢Jul 5, 8:00 PMjournal

    Agent 7 — Day Trader opened long 10 @ $204.58

48. ▣Jul 5, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 10 @ $206.35 (+$17.65)

    EOD forced close — day trader never carries overnight

49. ▢Jul 5, 8:00 PMjournal

    Agent 7 — Day Trader opened long 4 @ $204.58

50. ▣Jul 5, 8:00 PMjournaltarget

    Agent 7 — Day Trader closed long 4 @ $207.54 (+$11.84)

    Half-exit: close $207.54 ≥ +1.0% trigger $206.63. Selling 4/14 sh; stop ratchets to entry.

51. !Jul 2, 6:03 PMsignal

    options_momentum — insufficient_capital

52. !Jul 2, 5:45 PMsignal

    options_momentum — insufficient_capital

53. !Jul 2, 5:31 PMsignal

    options_momentum — insufficient_capital

54. !Jul 2, 5:16 PMsignal

    options_momentum — insufficient_capital

55. !Jul 2, 5:04 PMsignal

    options_momentum — insufficient_capital

56. !Jul 2, 4:46 PMsignal

    options_momentum — insufficient_capital

57. !Jul 2, 4:33 PMsignal

    options_momentum — insufficient_capital

58. !Jul 2, 4:16 PMsignal

    options_momentum — insufficient_capital

59. !Jul 2, 4:05 PMsignal

    options_momentum — insufficient_capital

60. !Jul 2, 3:46 PMsignal

    options_momentum — insufficient_capital

61. !Jul 2, 3:33 PMsignal

    options_momentum — insufficient_capital

62. !Jul 2, 3:17 PMsignal

    options_momentum — insufficient_capital

63. !Jul 2, 2:46 PMsignal

    options_momentum — insufficient_capital

64. !Jul 2, 2:33 PMsignal

    options_momentum — insufficient_capital

65. !Jul 2, 2:18 PMsignal

    options_momentum — insufficient_capital

66. !Jul 2, 2:07 PMsignal

    options_momentum — insufficient_capital

67. !Jul 2, 1:47 PMsignal

    options_momentum — insufficient_capital

68. !Jul 2, 1:35 PMsignal

    options_momentum — insufficient_capital

69. ?Jul 2, 12:36 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up ~1.95% today with no attributable headline, suggesting institutional flow rather than a news spike — which tends to be more durable. The macro context shows 10Y inflation expectations (T10YIE) running 1.6σ below trend at 2.23, which is supportive for long-duration sensitive sectors; IQV as a healthcare IT/CRO name has moderate duration sensitivity and benefits from lower real rate pressure. With 190 minutes remaining there is ample time for continuation. However, the move is below the 2% threshold where momentum becomes clearly compelling, there is no news catalyst to anchor buyers, and the absence of any sector-specific tailwind limits conviction. No reversal signal is present, and the setup is mildly positive. Assigning a modest continuation probability above the 0.5 trigger — momentum is real but not forceful enough to warrant high confidence.

70. ✓Jul 1, 9:46 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    IQV has moved +5.01% today with no attributable headline, suggesting institutional flow or a delayed reaction to sector-level catalyst (possibly contract news or earnings estimate revision). A 5% move without news often signals informed positioning rather than retail noise, lending credibility to continuation. However, several factors temper conviction: (1) 360 minutes remaining is a full trading day worth of time, which sounds like a lot but also means the move has had time to develop and may already be mature — early-session gap-ups on no news can fade as profit-taking sets in mid-day; (2) the macro context (T5YIE at 1.6σ below trend) points to lower real growth expectations, which is modestly unfavorable for HCIT/CRO names like IQV that benefit from steady pharma R&D spending — softer inflation breakevens can signal demand concerns; (3) no news means we cannot confirm whether the catalyst is durable. On balance, the move is large enough to respect as real flow, and the system's bounded downside (-1.5% stop) favors taking the trade, but the setup is ordinary momentum without clear confirmation of continuation pressure, so 0.55 is appropriate.

71. ❖Jul 1, 3:46 AMnewsvia finnhub

    Palo Alto To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, please see our analyst ratings page.

72. ❖Jul 1, 3:02 AMnewsvia finnhub

    Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $249

    Baird analyst Eric Coldwell maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $230 to $249.

73. ▢Jun 30, 8:00 PMjournal

    Agent 7 — Day Trader opened long 14 @ $201.75

74. ▣Jun 30, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 14 @ $203.19 (+$20.16)

    EOD forced close — day trader never carries overnight

75. ?Jun 25, 10:16 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up 2.76% today with no attributable headline, suggesting institutional flow or a sector rotation driving the move rather than a news catalyst that could quickly fade. With 329 minutes remaining (roughly 5.5 hours, indicating this is early-to-mid session), there is ample time for continuation if momentum holds. The macro context shows T10YIE at 2.4σ below trend, meaning inflation expectations are subdued and real yields are relatively elevated — this is a mixed signal for IQV (a CRO/healthcare data services company with moderate duration sensitivity). Lower inflation expectations can support growth-oriented healthcare names modestly, but IQV is not a pure long-duration play, so the macro tailwind is limited. The absence of news is not a disqualifier per the framework; the move itself represents real conviction. No reversal pattern is evident from the data provided. Overall, this is an ordinary momentum setup with no strong reason to expect a fade, supporting a modest continuation probability just above the action threshold.

76. ?Jun 24, 6:05 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a predominantly distributive story before today's spike. After a high-volume surge on 2026-05-28 (2.3M, +9.34%) and 2026-05-29 (2.6M, +0.62%), the stock spent three weeks churning and then declining — with the heaviest down-day volumes concentrated on the way lower: 2026-06-17 (1.9M, -4.74%), 2026-06-18 (3.7M, -1.70%), and 2026-06-22 (2.1M, near-flat). That 2026-06-18 bar at 3.7M is the single largest volume in the entire window and occurred on a down-day at a new low close of $167.77, a textbook distribution/selling-climax signature in the SIR scatter. Today's recovery bar (2026-06-24, $185.63, +8.38%) arrives on only 1.5M — a volume z-score of -0.36, i.e. below the 20-day mean ADV of 1.7M — meaning the sharp price advance is NOT accompanied by expanding volume, which in SIR's framework is a weak, unconfirmed move rather than a genuine cluster breakout. Risks: A true bullish invalidation of this read would require multiple subsequent sessions closing above $183–$187 on volume materially above the 1.7M ADV, demonstrating that today's gap-up is being absorbed by fresh demand rather than short-covering; conversely, any rollover back below $178 on elevated volume would confirm continued distribution and fully negate the single-bar recovery.

77. ?Jun 24, 7:04 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $4.36 cash available; close=$171.28.

78. ?Jun 24, 7:04 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

79. ?Jun 23, 10:25 AMdecisionconsidered

    Agent 7 — Day Trader — analyze: fail

    Claude analysis failed: Anthropic 500: {"type":"error","error":{"type":"api_error","message":"Internal server error"},"request_id":"req_011CcLM16n884xWx8SUzZ8i8"}

80. ?Jun 23, 8:51 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $19.16 cash available; close=$167.81.

81. ?Jun 23, 7:04 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

82. ?Jun 23, 7:03 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $19.16 cash available; close=$167.81.

83. ?Jun 22, 7:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $12.30 cash available; close=$167.81.

84. ?Jun 22, 7:21 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    IQV (IQVIA Holdings) is a large-cap CRO/data analytics firm with a historically strong balance sheet and recurring revenue base; no news headlines or SEC filings in the window indicate operational deterioration, guidance cuts, or accounting issues. The three recent 8-Ks carry no reported metrics and appear to be routine corporate filings. The 10.5% pullback from the 30-day high likely reflects broader macro headwinds — the yield curve (T10Y2Y at 0.38, 2.3σ below trend) points to a bear-flattening environment that pressures growth-oriented, debt-carrying companies like IQV, and sector rotation away from healthcare services/CROs has been a headwind in 2025-2026.

85. ?Jun 22, 6:06 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

86. ?Jun 22, 12:15 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down 1.56% today, a modest but real move with 210 minutes remaining — plenty of time for continuation or reversal. The move is below the 2-5% threshold that signals strong directional conviction, so the evidence of meaningful institutional flow is limited. No news headlines are available to explain the move, which is common and not disqualifying, but also means there is no narrative catalyst to sustain selling pressure into the close. The macro context (5Y inflation expectations 1.5σ below trend) is mildly disinflationary, which could modestly pressure healthcare/data services names like IQV if risk appetite softens, but IQV is not a primary reactor to TIPS/inflation dynamics. With no strong catalyst, moderate move size, and ample time remaining, this is a borderline read — no clear reason to fade, no strong reason to chase. Probability sits at the 0.5 floor, triggering a position per the system's rules given bounded downside risk.

87. ?Jun 22, 7:05 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

88. ?Jun 22, 7:05 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $1.92 cash available; close=$167.77.

89. ?Jun 18, 6:21 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    IQV (IQVIA Holdings) is a large-cap CRO/data analytics firm with a historically strong balance sheet and recurring revenue base; no news headlines or SEC filings in the window indicate operational deterioration, guidance cuts, or accounting issues. The three recent 8-Ks carry no reported metrics and appear to be routine corporate filings. The 10.5% pullback from the 30-day high likely reflects broader macro headwinds — the yield curve (T10Y2Y at 0.38, 2.3σ below trend) points to a bear-flattening environment that pressures growth-oriented, debt-carrying companies like IQV, and sector rotation away from healthcare services/CROs has been a headwind in 2025-2026.

90. ?Jun 18, 6:05 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] After the sharp thrust higher on 2026-05-28 ($181.09, 2.3M) and 2026-05-29 ($182.21, 2.6M), the PV path spent the June 1–12 period consolidating in the $180–$187 range on progressively shrinking volume (as low as 1.2M on June 8 and June 10), a hallmark of fading buying interest at elevated prices. The subsequent path then broke decisively lower: June 17 ($170.67, 1.9M, -4.74%) and today June 18 ($167.69, 2.4M, -1.75%, z-score +1.87) show the heaviest volume of the post-consolidation phase concentrated firmly on down days, dragging price back toward the pre-gap cluster near $162–$168. In 2-D PV space the path traces a classic distribution arc — up-right on the initial surge, stalling at high price/low volume, then moving down-right as sell-side volume expands, with no up-day volume confirmation to suggest accumulation. Risks: A decisive reclaim of the $181–$183 consolidation zone on volume materially above the 20-day ADV of 1.6M would invalidate the distribution read and suggest the recent selloff was a shakeout rather than genuine supply. Additionally, the macro backdrop (T10Y2Y at 3.5σ below trend on June 17) is not a primary headwind for Health Care/CROs like IQV, but any broader risk-off rotation amplifying down-day volume would accelerate the distributive path further.

91. ?Jun 18, 6:05 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

92. ?Jun 18, 6:04 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $1.52 cash available; close=$167.69.

93. ?Jun 18, 10:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is down ~2.92% with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven one-off. With 315 minutes (over 5 hours) remaining, there is ample time for the move to continue. However, the macro context is a mild headwind for continuation: the T10Y2Y spread is 3.5σ below its 24-month trend, favoring defensives and potentially pressuring healthcare IT/services names like IQV indirectly through risk-off rotation into defensives rather than away from them. The absence of news means we cannot confirm a fundamental catalyst driving sustained selling. The move is meaningful but sits at the lower end of the 2-5% significance range. No reversal pattern or volume anomaly is evident from available data. Overall, momentum modestly favors continuation into the close, but conviction is limited — assigning 0.52, just above the trigger threshold.

94. ?Jun 18, 7:03 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $10.13 cash available; close=$170.67.

95. ?Jun 18, 7:03 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

96. ?Jun 17, 6:06 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $11.35 cash available; close=$170.64.

97. ?Jun 17, 6:05 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IQV (IQVIA Holdings) is a well-established CRO/data analytics business with durable fundamentals — no confirmed earnings deterioration, guidance cut, or fraud is evident from the available filings. The 10.5% drop from the 30-day high appears more macro/sector-driven than company-specific, as the Health Care sector (XLV) has modest 30-day relative strength (+1.35pts vs SPY) but is showing recent weakness (-3.54pts over 5 days), suggesting a sector-wide pull rather than idiosyncratic impairment. However, confirmation signals are entirely absent: no insider cluster buying, no unusual call flow, no analyst upgrades, and no news catalysts to anchor a thesis.

98. ?Jun 17, 6:05 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    IQV (IQVIA Holdings) is a large-cap CRO/data analytics firm with a historically strong balance sheet and recurring revenue base; no news headlines or SEC filings in the window indicate operational deterioration, guidance cuts, or accounting issues. The three recent 8-Ks carry no reported metrics and appear to be routine corporate filings. The 10.5% pullback from the 30-day high likely reflects broader macro headwinds — the yield curve (T10Y2Y at 0.38, 2.3σ below trend) points to a bear-flattening environment that pressures growth-oriented, debt-carrying companies like IQV, and sector rotation away from healthcare services/CROs has been a headwind in 2025-2026.

99. ?Jun 4, 1:21 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    IQV is up 1.81% today, a modest but real move suggesting some institutional buying interest. There are no headlines to explain the move, which is common — flow-driven momentum can persist without a catalyst. The macro context (T10Y2Y at 2.1σ below trend) is modestly unfavorable for cyclical/growth names like IQV (a healthcare data/CRO company), as a flattening curve can signal risk-off sentiment. However, IQV is not in the most rate-sensitive bucket and the curve signal primarily weighs on banks. With 145 minutes remaining, there is ample time for the move to continue into the close. The move magnitude (1.81%) is below the 2-5% 'high conviction' threshold, suggesting moderate rather than strong directional pressure. No reversal signals or fade patterns are apparent from the data provided. Overall, a mild continuation bias with no strong counterarguments — probability sits at the lower end of the ordinary momentum range.

100. ?Jun 3, 10:20 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IQV is down 2.10% intraday with no headline catalyst identified, suggesting the move is driven by broader sector or market flow rather than a company-specific event. With 325 minutes remaining (essentially a full trading day still ahead), there is ample time for continuation but also for mean reversion. The macro context shows a compressed yield curve (T10Y2Y at 2.0σ below trend), which tends to pressure growth-oriented healthcare IT names like IQV as discount rates remain a concern. No reversal signals are evident from the data provided, and the move is in the meaningful 2-5% range indicating real selling conviction. However, the absence of a specific catalyst and the relatively moderate magnitude (not an extreme flush) temper conviction. The yield curve backdrop is modestly supportive of continued pressure on a high-multiple name in this sector. Overall, slight lean toward continuation of the downside move, but not a high-conviction setup.

101. ?Jun 2, 9:15 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IQV is up 2.53% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven pop that could reverse on profit-taking. The macro context (T10Y2Y at 0.42, 2.0σ below trend) points to a flatter/softer yield curve environment, which is modestly supportive for defensive growth names like IQV (healthcare IT/CRO space) relative to banks. With 390 minutes remaining (roughly the full remaining session), there is ample time for the move to extend. No reversal signals are noted — no fade pattern described, no abnormal volume flags. The absence of news is not disqualifying per framework. The move magnitude (2.53%) is meaningful but not extended enough to suggest immediate exhaustion. Overall, this is an ordinary momentum setup with no strong reason to expect a fade, landing in the 0.5–0.65 range.

102. ▣May 28, 8:00 PMjournalmanual

     options_momentum closed long 100 @ $3.04 (-$199.50)

     Stop: premium $1.46 ≤ trailing floor $3.93 (peak $5.24 × 0.75)

103. ❖May 28, 3:05 PMnewsvia finnhub

     Discover which S&P500 stocks are making waves on Thursday.

     Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Thursday.

104. ❖May 28, 12:35 PMnewsvia finnhub

     Discover which S&P500 stocks are making waves on Thursday.

     Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

105. ?May 28, 9:46 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     IQV is up 3.50% intraday with 360 minutes remaining — substantial time for the move to extend. The absence of news is not disqualifying; this magnitude of move reflects real institutional flow and conviction. Macro context shows T10Y3M at 1.8σ above trend, indicating a steepening yield curve environment which is modestly unfavorable for healthcare IT/services names like IQV (recession-sensitive sector overlay), creating mild headwind. However, with no specific negative catalyst and ample time remaining, the base rate for momentum continuation on a move of this size is slightly above even. No reversal or fade pattern is indicated from the data provided. The macro headwind from the yield curve context is modest enough not to override the momentum signal. Assigning a modest continuation probability above 0.5 — this is an ordinary momentum read with no strong reason to fade.

106. ?May 27, 6:01 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     Step 1: No hard veto fires — no imminent earnings, no fundamental deterioration signals, no sector freefall with concurrent macro credit stress. Step 2 net signal score: +1 (sector underperforming market, +1; no earnings within 30 days, +1; macro context neutral with VIX at only 35th percentile, +1) offset by negatives (10Y yield at 4.56% above ~4.5% threshold, -1; drop is only 11.3%, below the 15% threshold for mean-reversion bonus, 0; no insider cluster buy, no options flow, no confirming signals, -1 for sparse evidence with large negative sector flow proxy of -9M). Net score roughly +1. Step 3: Marginal score of +1 with no strong positive catalyst (no cluster buy, no unusual call flow) per framework rules warrants a skip. IQV (IQVIA) is a fundamentally sound CRO/data analytics business, but the sector is ranked 9/11 by 30-day relative strength with -9.03pts vs SPY over 30 days and a strongly negative flow proxy today, suggesting sector-wide headwinds rather than a simple dip. The absence of any insider buying, options flow, or recent filings leaves the thesis unsupported beyond base-rate mean reversion, which is penalized by the adverse sector backdrop and high yield environment.

107. ?May 27, 6:01 PMdecisionconsidered

     Agent 4 — Dip Buyer (Frozen) — decide: skip

     IQV (IQVIA Holdings) is a fundamentally sound contract research organization (CRO) with diversified revenue streams across clinical trials, data analytics, and technology solutions. The 11.3% drop from its 30-day high appears to reflect broader macro headwinds and sector rotation rather than company-specific deterioration — the only available headline is a neutral "hold" recommendation with no mention of guidance cuts or operational issues. However, the macro backdrop shows an inverted-to-normalizing yield curve (T10Y3M at +0.82, 1.9σ above trend), which historically signals late-cycle pressure on growth-oriented and capital-intensive sectors, and CROs like IQV can face near-term headwinds if pharma/biotech clients tighten R&D spending.

108. ?May 27, 6:01 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

     Wanted to buy but only $9.46 cash available; close=$162.00.

109. ❖May 27, 11:57 AMnewsvia finnhub

     Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now

     IQVIA's record $34.2B backlog, AI-led pharma demand and $1.24B buybacks support growth despite weak liquidity and no dividend.

110. ▢May 26, 8:00 PMjournal

     options_momentum opened long 100 @ $5.04

111. ❖May 26, 4:15 PMnewsvia finnhub

     IQVIA CEO to Speak at Jefferies Global Healthcare Conference

     RESEARCH TRIANGLE PARK, N.C., May 26, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:20 a.m. ET.

112. ❖May 26, 9:01 AMnewsvia finnhub

     What Makes IQVIA Holdings (IQV) an Investment Bet?

     Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for “Artisan Value Fund”. A copy of the letter is available to download here. The Funds’ Investor Class: ARTLX, Advisor Class: APDLX, and Institutional Class: APHLX returned -3.54%, -3.50%. and 3.50%, respectively, in Q1 vs, 2.10% return for the Russell 1000® Value Index. Performance […]

113. ❖May 25, 12:30 PMnewsvia finnhub

     Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead

     VEEV's growing Vault CRM adoption and AI momentum, backed by major pharma wins, reinforce confidence in its long-term growth outlook.